Quantcast

Latest BioInvent International AB Stories

2011-05-16 00:30:00

LEUVEN, Belgium and LUND, Sweden, May 16, 2011 /PRNewswire-FirstCall/ -- - Two New Studies Now Ongoing: Phase Ib/II in Patients With Aggressive Brain Tumour and Phase Ib in Primary Liver Cancer ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334)....

2011-04-27 00:30:00

LEUVEN, Belgium and LUND, Sweden, April 27, 2011 /PRNewswire-FirstCall/ -- - Trial to Assess the Benefits of Partial Factor VIII Inhibition in Total Hip Replacement Surgery Patients ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 (Anti-Factor VIII) for the prophylaxis of venous thromboembolism (VTE)...

2011-02-11 00:29:00

LEUVEN, Belgium and LUND, Sweden, February 11, 2011 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the positive TB-402 (Anti-Factor VIII) Phase II trial results, evaluating the product's efficacy and safety for the prevention of venous thromboembolism (VTE) afterorthopaedic surgery, have been published in the Journal of Thrombosis and Haemostasis. A paper entitled "Single...

2010-05-17 00:29:00

LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ -- - Trial to Study Patients with Colorectal and Ovarian Cancer ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and...

2010-05-06 00:29:00

LEUVEN, Belgium and LUND, Sweden, May 6, 2010 /PRNewswire-FirstCall/ -- - TB-402 Demonstrates Superior Antithrombotic Activity to Enoxaparin ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic...

2009-11-16 10:45:00

LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related